A Phase 3 interventional study of Crovalimab in Atypical Hemolytic Uremic Syndrome, sponsored by Hoffmann-La Roche. Active, not recruiting at 41 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States — 3 open to participants now, 5 under way, 2 of them phase 3. Atypical Hemolytic Uremic Syndrome · United States.
Among the 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 16th registered.
45 studies on the registry are indexed under Atypical Hemolytic Uremic Syndrome; 14 are open to participants now.
Browse Atypical Hemolytic Uremic Syndrome studies →3 of the 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States are open now. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, Belgium and 14 more countries
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Atypical Hemolytic Uremic Syndrome studies recruiting now, 10 (83%) set no upper age limit and none (0%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2021.
This study's enrollment of 83 is above the median of 34 across 26 interventional studies indexed under Atypical Hemolytic Uremic Syndrome.
Median enrollment 34 across the 13 interventional studies, 75 across the 7 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 8 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Atypical Hemolytic Uremic Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Atypical Hemolytic Uremic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be enrolled in three cohorts: \[1\] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; \[2\] Switch Cohort - participants who switch to crovalimab from another Complement Component 5 (C5) inhibitor and \[3\] C5 Single Nucleotide Polymorphism (C5 inhibitor) Cohort - participants with documented C5 polymorphism.
Drug: Crovalimab
Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).
Naive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25
cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: platelet count ≥ lower limit of normal (LLN); lactate dehydrogenase (LDH) ≤ upper limit of normal (ULN); and ≥25% decrease in serum creatinine from baseline. Participants with normalized creatinine (i.e., LLN ≤ creatinine ≤ ULN) at baseline were excluded from analysis. Percentage has been rounded off.
Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
Naive and Switch Cohorts: Percentage of Participants Requiring Dialysis at Baseline and at Week 25 Who Completed 24 Weeks of Treatment
Participants were considered to be on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. The percentage of participants who required dialysis at baseline and Week 25 has been reported here. Percentages have been rounded off.
Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
Naïve and Switch Cohorts: Percentage of Participants With Change From Baseline to Week 25 (After 24 Weeks on Treatment) on Dialysis Status (Yes/No)
Participants were considered as being on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. Participants who were on dialysis at any time point from baseline to Week 25 were classified as "Initiated dialysis at any time point ". Participants who remained dialysis-free throughout the primary treatment period were classified as "Remained dialysis free throughout". Participants who were on dialysis at Week 25 were classified as "Remained on dialysis". Participants who discontinued dialysis at Week 25 were classified as "Discontinued dialysis. Percentages have been rounded off.
Time frame: From baseline up to Week 25
Naive and Switch Cohorts: Observed Values of Estimated Glomerular Filtration Rate (eGFR), as Calculated From Central Serum Creatinine
GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to chronic kidney disease (CKD) staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD-Epidemiology Collaboration (EPI) creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (milliliters per minute per 1.73 square meter \[mL/min/1.73 m\^2\])=0.413\*(height \[ht\]/serum creatinine \[sCr\]), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.
Time frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
Naive and Switch Cohorts: Change From Baseline up to Week 25 in eGFR, as Calculated From Central Serum Creatinine
GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to CKD staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD- EPI creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (mL/min/1.73 m\^2)=0.413\*(ht/sCr), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.
Time frame: Baseline, Weeks 2, 3, 4, 5, 7, 9, 13, 17, 21, and 25
Naive and Switch Cohorts: Percentage of Participants With Change in Chronic Kidney Disease (CKD) Stage From Baseline to Week 25, as Assessed Based on eGFR Calculated From Central Serum Creatinine
CKD stage assessed using eGFR, classified per National Kidney Foundation CKD staging criteria: grade 1 (≥90 mL/min/1.73 m²; normal or high), grade 2 (60-89 mL/min/1.73 m²; mildly decreased), grade 3a (45-59 mL/min/1.73 m²; mildly to moderately decreased), grade 3b (30-44 mL/min/1.73 m²; moderately to severely decreased), grade 4 (15-29 mL/min/1.73 m²; severely decreased), grade 5 (\<15 mL/min/1.73 m²; kidney failure). Change in CKD stage from baseline to Week 25, categorized as improved (participants who improved in CKD stage from baseline to Week 25 were based on number of participants who completed 24 weeks \& were not stage 1 at baseline), stable (no change), or worsened (CKD stage 1-4 at baseline) among participants who completed 24 weeks of treatment. Percentages rounded off.
Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
Naive and Switch Cohorts: Observed Value of Platelet Count
Time frame: Baseline and Week 25
Naive and Switch Cohorts: Observed Value of Lactate Dehydrogenase (LDH)
Time frame: Baseline and Week 25
Naive and Switch Cohorts: Observed Value of Hemoglobin
Time frame: Baseline and Week 25
Naive and Switch Cohorts: Change From Baseline in Platelet Count at Week 25
Time frame: Baseline and Week 25
Naive and Switch Cohorts: Change From Baseline in LDH at Week 25
Time frame: Baseline and Week 25
Naive and Switch Cohorts: Change From Baseline in Hemoglobin at Week 25
Time frame: Baseline and Week 25
Naive and Switch Cohorts: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 25
Fatigue was measured by the FACIT-Fatigue questionnaire in adult participants only (≥18 years at baseline). It consists of 13 items that assess fatigue using a 7-day recall period. Items are scored on a 0= 'Not at all' to 4= 'Very much so' response scale. Relevant items are reverse scored, and all items are summed to create total score where higher scores are indicative of better functioning (i.e., less fatigue). The FACIT-Fatigue total score ranges from 0 to 52, with higher scores representing less fatigue; therefore, an increase in score represents an improvement in fatigue. Only categories with non-zero values were reported.
Time frame: Baseline, Weeks 1 (Day 1), 2, 5, 9, 17, and 25
Naive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
This event was confirmed at two separate assessments obtained at least 4 weeks (a minimum of 26 days) apart and any measurement in between. Percentages are rounded off.
Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
Naive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
Percentages are rounded off.
Time frame: From baseline through Week 25 (after 24 weeks on treatment)
Naive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment)
Percentages are rounded off.
Time frame: Baseline up to Week 25 (after 24 weeks on treatment)
Naive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr)
cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Kaplan-Meier (K-M) method was used to estimate median time to cTMAr. Data for participants who did not reach cTMAr during the primary treatment period were censored at the date of their last visit when cTMAr was assessed during the primary treatment period or prior to the treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy during the primary treatment period were censored at the date of the first received prohibited therapy during the primary treatment period or prior to the treatment discontinuation, whichever was earlier.
Time frame: From baseline up to Week 25
Naive Cohort: Duration of cTMAr
cTMAr was defined by meeting following criteria at 2 separate assessments, obtained at least 4 weeks (minimum of 26 days) apart \& any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; \& ≥25% decrease in serum creatinine from baseline \& \> ULN. Duration of cTMAr was calculated as time from start of cTMAr to end of cTMAr. End of cTMAr was when all above-mentioned criteria were met during same visit \& confirmed at an assessment that took place at least 4 weeks (minimum of 26 days) later. K-M method was used to estimate median duration of cTMAr. Data for participants with no observed end of cTMAr at clinical cutoff date (CCOD) were censored at the date of their last visit when cTMAr was assessed before CCOD or before treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy prior to the CCOD were censored at date of the first received prohibited therapy or prior to the treatment discontinuation, whichever was earlier.
Time frame: From baseline up to primary CCOD (up to 207 weeks)
Naive Cohort: Percentage of Participants With cTMAr Ongoing at Week 25
cTMAr at Week 25 was defined by meeting all of the three cTMAr criteria at Week 25: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Percentage has been rounded off.
Time frame: At Week 25
Switch Cohort: Percentage of Participants With Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (After 24 Weeks on Treatment)
mTMAc was considered not maintained if all of the following criteria were met during one of the visits between baseline and Week 25, and were confirmed at an assessment that took place at least 4 weeks (a minimum of 26 days) later: Platelet count \< LLN; LDH \> ULN; and 25% increase in serum creatinine from baseline and \> ULN.
Time frame: From baseline through Week 25 (After 24 weeks on treatment)
All Cohorts: Number of Participants With AEs
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to approximately 8 years
All Cohorts: Number of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension and Infections
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Infusion-related and injection-site reactions were adverse events that occured during or within 24 hours after crovalimab administration and were judged to be related to study drug infusion or injection.
Time frame: Up to approximately 8 years
All Cohorts: Number of Participants With AE Leading to Study Drug Discontinuation
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to approximately 8 years
Switch Cohort: Number of Participants With Clinical Manifestations of Drug-target-drug Complexes (DTDCs)
In this study, the risk of DTDC is relevant only to participants who might switch to crovalimab from eculizumab or ravulizumab treatment at study enrollment, and to participants who discontinued crovalimab and switch to eculizumab or ravulizumab. Type III hypersensitivity may occur due to the transient formation of DTDCs made of eculizumab or ravulizumab, crovalimab, and C5 in participants switching from eculizumab or ravulizumab to crovalimab.
Time frame: Up to approximately 8 years
All Cohorts: Crovalimab Serum Concentration
Time frame: Up to approximately 8 years
All Cohorts: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Crovalimab
Participants will be considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).
Time frame: Up to approximately 8 years
All Cohorts: Observed Value of Complement Activity (CH50) Over Time, as Measured by Liposome Immunoassay (LIA)
Time frame: Up to approximately 8 years
All Cohorts: Change From Baseline in CH50 Over Time, as Measured by LIA
Time frame: Up to approximately 8 years
All Cohorts: Observed Value of Free Complement Component 5 (C5) Concentrations in Crovalimab-treated Participants
Time frame: Up to approximately 8 years
All Cohorts: Change From Baseline in Free C5 Concentrations Over Time in Crovalimab-treated Participants
Time frame: Up to approximately 8 years
All Cohorts: Observed Value of Total C5 Concentrations in Crovalimab-treated Participants
Time frame: Up to approximately 8 years
All Cohorts: Change From Baseline in Total C5 Concentrations in Crovalimab-treated Participants
Time frame: Up to approximately 8 years
A total of 83 participants were enrolled at 42 investigative sites across 16 countries. Participants were planned to be enrolled in 3 parallel cohorts, based on their previous exposure \& response to complement inhibitor therapy: Naïve, Switch, \& component 5 (C5) single nucleotide polymorphism (SNP) (documented C5 polymorphism) cohorts.
| Milestone | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort |
|---|---|---|---|
| Started | 41 | 41 | 1 |
| Efficacy evaluable population | 37 | 41 | 0 |
| Completed | 34 | 39 | 0 |
| Not completed | 7 | 2 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Ahus misdiagnosis | 0 | 0 | 1 |
| Withdrew: Entered sfu | 5 | 1 | 0 |
| Milestone | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort |
|---|---|---|---|
| Started | 27 | 36 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 27 | 36 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Entered sfu | 3 | 0 | 0 |
| Withdrew: Ongoing study treatment | 23 | 35 | 0 |
| Milestone | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort |
|---|---|---|---|
| Started | 13 | 4 | 1 |
| Completed | 7 | 1 | 1 |
| Not completed | 6 | 3 | 0 |
| Withdrew: Ongoing in study | 2 | 2 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: platelet count ≥ lower limit of normal (LLN); lactate dehydrogenase (LDH) ≤ upper limit of normal (ULN); and ≥25% decrease in serum creatinine from baseline. Participants with normalized creatinine (i.e., LLN ≤ creatinine ≤ ULN) at baseline were excluded from analysis. Percentage has been rounded off.
| percentage of participants | Crovalimab Naive Cohort |
|---|---|
| Naive Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25 | 59.5 (43.49 to 73.65) |
Participants were considered to be on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. The percentage of participants who required dialysis at baseline and Week 25 has been reported here. Percentages have been rounded off.
| percentage of participants | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Baseline | 53.1 (36.45 to 69.13) | 0 (0.00 to 8.97) |
| Week 25 | 3.1 (0.55 to 15.74) | 0 (0.00 to 8.97) |
Participants were considered as being on dialysis at baseline or at Week 25 if dialysis occurred within 5 days prior to the first crovalimab administration or prior to the end date of the primary treatment period, respectively. Participants who were on dialysis at any time point from baseline to Week 25 were classified as "Initiated dialysis at any time point ". Participants who remained dialysis-free throughout the primary treatment period were classified as "Remained dialysis free throughout". Participants who were on dialysis at Week 25 were classified as "Remained on dialysis". Participants who discontinued dialysis at Week 25 were classified as "Discontinued dialysis. Percentages have been rounded off.
| percentage of participants | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Initiated Dialysis at Any Timepoint | 12.5 | 0 |
| Discontinued Dialysis | 53.1 | 0 |
| Remained on Dialysis | 0 | 0 |
| Remained Dialysis-free Throughout | 34.4 | 100 |
GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to chronic kidney disease (CKD) staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD-Epidemiology Collaboration (EPI) creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (milliliters per minute per 1.73 square meter \[mL/min/1.73 m\^2\])=0.413\*(height \[ht\]/serum creatinine \[sCr\]), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.
| mL/min/1.73 m^2 | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Baseline | 22.11 ± 16.42 | 67.36 ± 32.73 |
| Week 2 | 28.32 ± 22.31 | 68.32 ± 32.42 |
| Week 3 | 34.75 ± 26.63 | 65.68 ± 33.38 |
| Week 4 | 47.16 ± 31.87 | 66.31 ± 33.18 |
| Week 5 | 50.59 ± 30.79 | 66.06 ± 33.07 |
| Week 7 | 54.93 ± 31.72 | 67.12 ± 32.53 |
| Week 9 | 51.66 ± 31.98 | 67.55 ± 30.7 |
| Week 13 | 54.88 ± 30.34 | 69.25 ± 29.3 |
| Week 17 | 54.73 ± 30.86 | 67.00 ± 29.77 |
| Week 21 | 57.82 ± 31.24 | 68.71 ± 31.53 |
| Week 25 | 58.49 ± 28.11 | 66.61 ± 30.54 |
GFR is an index of kidney function that describes the flow rate of filtered fluid through the kidneys. It was categorized according to CKD staging criteria. eGFR was calculated using the creatinine-based bedside Schwartz equation for adolescents and 2009 CKD- EPI creatinine equation for adults. Formula for creatinine-based bedside Schwartz equation was eGFR (mL/min/1.73 m\^2)=0.413\*(ht/sCr), if height is expressed in centimeters, or 41.3\*(ht/sCr), if height is expressed in meters, and formula for 2009 CKD-EPI creatinine equation was eGFR (mL/min/1.73 m\^2)= 141\*min(sCr /κ,1)\^α\*max(sCr/κ,1)\^ -1.209\*0.993\^AGE\[\*1.018 if female\]\[\*1.159 if black\], κ was 0.7 for females and 0.9 for males, α was -0.329 for females and -0.411 for males, min indicated the minimum of sCr/κ or 1, and max indicated the maximum of sCr/κ or 1.
| mL/min/1.73 m^2 | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Change at Week 2 | 6.3 ± 10.93 | 0.96 ± 5.17 |
| Change at Week 3 | 11.87 ± 15.67 | -1.68 ± 7.45 |
| Change at Week 4 | 22.72 ± 26.95 | -0.93 ± 6.94 |
| Change at Week 5 | 24.7 ± 27.95 | -1.61 ± 7.43 |
| Change at Week 7 | 30.26 ± 29.17 | -1.64 ± 7.93 |
| Change at Week 9 | 27.64 ± 27.22 | -1.49 ± 9.46 |
| Change at Week 13 | 30.81 ± 24.75 | -2.42 ± 10.07 |
| Change at Week 17 | 30.97 ± 26.24 | -1.5 ± 9.33 |
| Change at Week 21 | 33.41 ± 25.94 | -0.33 ± 9.23 |
| Change at Week 25 | 33.9 ± 23.94 | -2.43 ± 9.36 |
CKD stage assessed using eGFR, classified per National Kidney Foundation CKD staging criteria: grade 1 (≥90 mL/min/1.73 m²; normal or high), grade 2 (60-89 mL/min/1.73 m²; mildly decreased), grade 3a (45-59 mL/min/1.73 m²; mildly to moderately decreased), grade 3b (30-44 mL/min/1.73 m²; moderately to severely decreased), grade 4 (15-29 mL/min/1.73 m²; severely decreased), grade 5 (\<15 mL/min/1.73 m²; kidney failure). Change in CKD stage from baseline to Week 25, categorized as improved (participants who improved in CKD stage from baseline to Week 25 were based on number of participants who completed 24 weeks \& were not stage 1 at baseline), stable (no change), or worsened (CKD stage 1-4 at baseline) among participants who completed 24 weeks of treatment. Percentages rounded off.
| percentage of participants | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Improved in CKD Stage | 78.1 (61.25 to 88.98) | 17.2 (7.6 to 34.55) |
| Worsened in CKD Stage | 0 (0 to 16.82) | 13.5 (5.91 to 27.98) |
| Stable (no Change) in CKD Stage | 9.4 (3.24 to 24.22) | 71.8 (56.22 to 83.46) |
| cells*10^9 per liter (cells*10^9/L) | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Baseline | 171.5 ± 116.6 | 246.5 ± 72.3 |
| Week 25 | 229.3 ± 65.4 | 241.2 ± 67.7 |
| units per liter (U/L) | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Baseline | 392.1 ± 352.0 | 134.1 ± 21.8 |
| Week 25 | 137.1 ± 35.8 | 142.0 ± 44.5 |
| grams per liter (g/L) | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Baseline | 92.3 ± 16.7 | 141.4 ± 17.8 |
| Week 25 | 127.6 ± 17.5 | 140.4 ± 15.1 |
| cells*10^9/L | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Naive and Switch Cohorts: Change From Baseline in Platelet Count at Week 25 | 57.9 ± 108 | -4.9 ± 38.4 |
| U/L | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Naive and Switch Cohorts: Change From Baseline in LDH at Week 25 | -211.6 ± 186.2 | 7.3 ± 40.4 |
| g/L | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Naive and Switch Cohorts: Change From Baseline in Hemoglobin at Week 25 | 35 ± 18.9 | -1.7 ± 9.4 |
Fatigue was measured by the FACIT-Fatigue questionnaire in adult participants only (≥18 years at baseline). It consists of 13 items that assess fatigue using a 7-day recall period. Items are scored on a 0= 'Not at all' to 4= 'Very much so' response scale. Relevant items are reverse scored, and all items are summed to create total score where higher scores are indicative of better functioning (i.e., less fatigue). The FACIT-Fatigue total score ranges from 0 to 52, with higher scores representing less fatigue; therefore, an increase in score represents an improvement in fatigue. Only categories with non-zero values were reported.
| scores on a scale | Crovalimab Naive Cohort | Crovalimab Switch Cohort |
|---|---|---|
| Baseline | 30.74 ± 14.68 | 40.95 ± 8.35 |
| Change at Week 2 | 4.01 ± 7.87 | 2.22 ± 4.46 |
| Change at Week 5 | 6.06 ± 9.26 | 1.23 ± 5.37 |
| Change at Week 9 | 7.49 ± 11.54 | 1.65 ± 5.96 |
| Change at Week 17 | 8.68 ± 12.82 | 1.24 ± 5.93 |
| Change at Week 25 | 8.36 ± 11.75 | 0.41 ± 8.76 |
This event was confirmed at two separate assessments obtained at least 4 weeks (a minimum of 26 days) apart and any measurement in between. Percentages are rounded off.
| percentage of participants | Crovalimab Naive Cohort |
|---|---|
| Naive Cohort: Percentage of Participants With Platelet Count ≥ LLN at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment) | 81.1 (65.8 to 90.52) |
Percentages are rounded off.
| percentage of participants | Crovalimab Naive Cohort |
|---|---|
| Naive Cohort: Percentage of Participants With LDH ≤ Upper Limit of Normal (ULN) at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment) | 83.8 (68.86 to 92.35) |
Percentages are rounded off.
| percentage of participants | Crovalimab Naive Cohort |
|---|---|
| Naive Cohort: Percentage of Participants With ≥25% Decrease in Serum Creatinine From Baseline at Two Separate Assessments, Obtained at Least 4 Weeks Apart (Minimum of 26 Days), by Week 25 (After 24 Weeks on Treatment) | 64.9 (48.76 to 78.17) |
cTMAr was defined by meeting all of the following criteria at two separate assessments, obtained at least 4 weeks (a minimum of 26 days) apart, and any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Kaplan-Meier (K-M) method was used to estimate median time to cTMAr. Data for participants who did not reach cTMAr during the primary treatment period were censored at the date of their last visit when cTMAr was assessed during the primary treatment period or prior to the treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy during the primary treatment period were censored at the date of the first received prohibited therapy during the primary treatment period or prior to the treatment discontinuation, whichever was earlier.
| weeks | Crovalimab Naive Cohort |
|---|---|
| Naive Cohort: Time to Complete Thrombotic Microangiopathy Response (cTMAr) | 12.1 (6.3 to 16.0) |
cTMAr was defined by meeting following criteria at 2 separate assessments, obtained at least 4 weeks (minimum of 26 days) apart \& any measurement in between: Platelet count ≥ LLN; LDH ≤ ULN; \& ≥25% decrease in serum creatinine from baseline \& \> ULN. Duration of cTMAr was calculated as time from start of cTMAr to end of cTMAr. End of cTMAr was when all above-mentioned criteria were met during same visit \& confirmed at an assessment that took place at least 4 weeks (minimum of 26 days) later. K-M method was used to estimate median duration of cTMAr. Data for participants with no observed end of cTMAr at clinical cutoff date (CCOD) were censored at the date of their last visit when cTMAr was assessed before CCOD or before treatment discontinuation, whichever was earlier. Data for participants who received a prohibited therapy prior to the CCOD were censored at date of the first received prohibited therapy or prior to the treatment discontinuation, whichever was earlier.
| weeks | Crovalimab Naive Cohort |
|---|---|
| Naive Cohort: Duration of cTMAr | NA (NA to NA) |
cTMAr at Week 25 was defined by meeting all of the three cTMAr criteria at Week 25: Platelet count ≥ LLN; LDH ≤ ULN; and ≥ 25% decrease in serum creatinine from baseline and \> ULN. Percentage has been rounded off.
| percentage of participants | Crovalimab Naive Cohort |
|---|---|
| Naive Cohort: Percentage of Participants With cTMAr Ongoing at Week 25 | 54.1 (38.38 to 68.96) |
mTMAc was considered not maintained if all of the following criteria were met during one of the visits between baseline and Week 25, and were confirmed at an assessment that took place at least 4 weeks (a minimum of 26 days) later: Platelet count \< LLN; LDH \> ULN; and 25% increase in serum creatinine from baseline and \> ULN.
| percentage of participants | Crovalimab Switch Cohort |
|---|---|
| Switch Cohort: Percentage of Participants With Maintained Thrombotic Microangiopathy Control (mTMAc) From Baseline Through Week 25 (After 24 Weeks on Treatment) | 100 (91.43 to 100) |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Infusion-related and injection-site reactions were adverse events that occured during or within 24 hours after crovalimab administration and were judged to be related to study drug infusion or injection.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Results for this outcome have not been posted.
In this study, the risk of DTDC is relevant only to participants who might switch to crovalimab from eculizumab or ravulizumab treatment at study enrollment, and to participants who discontinued crovalimab and switch to eculizumab or ravulizumab. Type III hypersensitivity may occur due to the transient formation of DTDCs made of eculizumab or ravulizumab, crovalimab, and C5 in participants switching from eculizumab or ravulizumab to crovalimab.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Participants will be considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples is at least 4-fold greater than the titer of the baseline sample (treatment-enhanced ADA response).
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to approximately 207 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crovalimab Naive Cohort | 3/41 (7.3%) | 14/41 (34.1%) | 33/41 (80.5%) |
| Crovalimab Switch Cohort | 0/41 (0%) | 10/41 (24.4%) | 39/41 (95.1%) |
| Crovalimab C5 SNP Cohort | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort |
|---|---|---|---|
| Castleman's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/41 | 0/41 | 1/1 |
| Thrombotic microangiopathyBlood and lymphatic system disorders | 2/41 | 1/41 | 0/1 |
| PneumoniaInfections and infestations | 2/41 | 2/41 | 0/1 |
| Pyelonephritis acuteInfections and infestations | 0/41 | 2/41 | 0/1 |
| Urinary tract infectionInfections and infestations | 2/41 | 2/41 | 0/1 |
| Atypical haemolytic uraemic syndromeBlood and lymphatic system disorders | 1/41 | 0/41 | 0/1 |
| Cardiac arrestCardiac disorders | 1/41 | 0/41 | 0/1 |
| Cardiac failure congestiveCardiac disorders | 1/41 | 0/41 | 0/1 |
| MyocarditisCardiac disorders | 1/41 | 0/41 | 0/1 |
| Wellens' syndromeCardiac disorders | 1/41 | 0/41 | 0/1 |
| Event | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort |
|---|---|---|---|
| Nephrogenic anaemiaBlood and lymphatic system disorders | 1/41 | 1/41 | 1/1 |
| Ear congestionEar and labyrinth disorders | 0/41 | 0/41 | 1/1 |
| GastritisGastrointestinal disorders | 2/41 | 1/41 | 1/1 |
| StomatitisGastrointestinal disorders | 0/41 | 0/41 | 1/1 |
| PainGeneral disorders | 0/41 | 1/41 | 1/1 |
| Hepatic enzyme increasedInvestigations | 1/41 | 0/41 | 1/1 |
| White blood cell count decreasedInvestigations | 1/41 | 0/41 | 1/1 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/41 | 0/41 | 1/1 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/41 | 0/41 | 1/1 |
| DysgeusiaNervous system disorders | 0/41 | 0/41 | 1/1 |
All participants population included all enrolled participants in the study.
| Age, Continuous(years) | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort | Total |
|---|---|---|---|---|
| Mean | 37.7 ± 13.5 | 35.6 ± 16.7 | 55.0 ± NA | 36.9 ± 15.2 |
| Sex: Female, Male(Participants) | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort | Total |
|---|---|---|---|---|
| Female | 24 | 27 | 0 | 51 |
| Male | 17 | 14 | 1 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort | Total |
|---|---|---|---|---|
| Hispanic or Latino | 12 | 11 | 0 | 23 |
| Not Hispanic or Latino | 23 | 27 | 1 | 51 |
| Unknown or Not Reported | 6 | 3 | 0 | 9 |
| Race (NIH/OMB)(Participants) | Crovalimab Naive Cohort | Crovalimab Switch Cohort | Crovalimab C5 SNP Cohort | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 2 |
| Asian | 12 | 0 | 1 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 21 | 37 | 0 | 58 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 5 | 3 | 0 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Oct 2021 to primary completion in Oct 2025, 47 months.
Results were first posted in Oct 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Crovalimab
Atypical Hemolytic Uremic Syndrome →